Houston, May 28, 2025 (GLOBE NEWSWIRE) — Houston, Texas –
HOUSTON, TX – While LASIK has long been considered the gold standard for vision correction, Houston LASIK & Eye is highlighting an important truth: LASIK isn’t the ideal solution for everyone seeking freedom from glasses and contact lenses. The renowned vision center announces its introduction of EVO ICL (Implantable Collamer Lens) technology, offering a personalized alternative for patients previously considered unsuitable for laser vision correction.
“Not everyone is an ideal candidate for LASIK, particularly those with thin corneas or severe dry eye,” explains Dr. Amjad Khokhar, Medical Director at Houston LASIK & Eye. “With EVO ICL, we’re excited to offer these patients a revolutionary option that delivers exceptional visual results without removing corneal tissue.” Dr. Khokhar is the first Fort Bend surgeon to implant ICL technology.
The EVO ICL by STAAR Surgical represents a significant advancement in vision correction technology. This biocompatible, collagen-based lens is implanted through a tiny incision between the iris and the natural lens, requiring no reshaping of the cornea. The 15-minute procedure produces sharp, clear vision while avoiding complications associated with dry eye syndrome, which is a common concern following traditional laser procedures.
What sets EVO ICL apart is its versatility and reversibility. Unlike LASIK, the implant can be removed if necessary, though it requires no maintenance once in place. The lens corrects nearsightedness up to -20.00 diopters, making it suitable for patients with higher prescriptions who might be ineligible for LASIK.
“At Houston LASIK & Eye, we believe everyone deserves access to premium vision correction tailored to their unique needs,” continues Dr. Khokhar. “Our approach has always been personalized care, not a one-size-fits-all solution.”
Since its founding in 2005, Houston LASIK & Eye has built a global reputation for excellence, attracting patients from across the United States and internationally. The center’s commitment to cutting-edge technology and personalized treatment has made it a destination of choice for even NASA astronauts and Air Force fighter pilots seeking vision correction.
Ideal candidates for EVO ICL include adults between 21 and 45 years old with no history of eye disease or previous ophthalmic surgery. The lens offers several advantages beyond vision correction, including UV protection and reduced glare, with patients typically experiencing rapid recovery and minimal discomfort.
“The ‘Personal LASIK Experience’ that our center is known for extends to all our vision correction services,” adds Dr. Khokhar. “From the complimentary initial consultation through post-procedure care, patients receive compassionate, professional attention in a relaxing environment.”
This innovative procedure, which offers an alternative for patients who may not be ideal candidates for traditional LASIK surgery, exemplifies Houston LASIK & Eye’s commitment to staying at the forefront of ophthalmic advancements while ensuring each patient receives the most appropriate treatment for their unique vision challenges.
With locations in Houston, Sugar Land, and Pearland, Houston LASIK & Eye continues to advance its mission of providing high-quality, technologically sophisticated eye care in a comfortable setting. The addition of the EVO ICL to its comprehensive service offerings reinforces the center’s dedication to meeting diverse patient needs with customized vision solutions.
Patients interested in learning whether the EVO ICL might be right for them are encouraged to schedule a complimentary consultation by calling Houston LASIK & Eye at 281-240-0478 or visiting their website for more information and to view patient testimonials and success stories.
###
For more information about Houston LASIK & Eye, contact the company here:
Houston LASIK & Eye
Dr. Amjad Khokhar,
(281) 240-0478
info@houston-lasik.com
7737 Southwest Freeway, Suite 350,
Houston, TX 77074
CONTACT: Dr. Amjad Khokhar,
- Allot Announces Pricing of UnderwrittenPublic Offering of Ordinary Shares - June 24, 2025
- Air Methods Expands Bell 429 Fleet to Support Partners - June 24, 2025
- Cidara Announces Pricing of Upsized Public Offering of Common Stock - June 24, 2025
